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ABSTRACT

Objective
To systematically review the potential efficacy, safety and technical aspects of
cryoablation in the treatment of venous malformations, and provide the groundwork for
future prospective studies.

Materials and Methods
Venous malformations (VMs) are a common slow-flow type congenital vascular
malformation made up of a “mass-like” network of dysplastic venous structures. A
systematic review was performed following the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines. A search in PubMed and Google
Scholar for clinical studies utilizing percutaneous cryoablation of VMs was performed
and all relevant articles were then manually reviewed. Prospective, retrospective and
case studies related to primary or secondary treatment of venous malformations with
percutaneous cryoablation were included for review. These selected studies were then
evaluated for: patient characteristics, cryoablation technique, technical success rate (as
defined by the ice ball covering the entire lesion), pre and post lesion size, pre and post
pain scores (scored 1-10 with 10 being the worst pain), and adverse outcomes. The
methodologic quality of these studies were analyzed utilizing the Newcastle-Ottawa
Quality Assessment Scale (NOS). Random effects model was utilized to compute the
standardized mean differences in the pre- and post-procedural volume and pain score
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changes. A funnel plot was performed to assess standardized mean differences between
the studies.

Results
There were 54 patients with 55 cases of cryoablation for VMs identified. Of these cases,
27 cases recorded change of lesion volume, and 31 recorded changes in pain scores. The
weighted mean post-procedure decrease in lesion size was 92.0% (raw average of
71.7%). The weighted mean reduction in pain score was 77% (raw average of 78.2%),
with 20 of 31 cases (64.5%) reporting complete resolution of pain and complete or
partial improvement in 94.5% of patients. Common post-procedural symptoms included
pain, bruising, swelling and numbness, lasting under two weeks. There were two major
adverse events (3.7%), with both cases due to persistent dysesthesia. Patients with
history of prior sclerotherapy demonstrated lower pre- and post-procedural pain scores
(4.7 and 1.3), compared with patients without prior treatments (5.8 and 2.8).

Conclusions
Cryoablation of venous malformations appears to be potentially safe and effective on
limited short-interval follow-up. Larger prospective studies with longer follow-up
periods are needed.
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Key Points


Cryoablation of venous malformations appears to be effective in reducing pain
and lesion size, with 63.6% of patients reporting complete resolution in pain and
94.5% with overall improvement.



Initial and post-procedural pain scores were lower in patients with prior
sclerotherapy. However, a significant difference in the reduction of pain and
lesion size between the two groups was not observed.



Major adverse events occurred in 3.7% of the treated population, with all cases
due to persistent dysesthesia at final follow-up.
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INTRODUCTION

Background
Venous malformation (VM) is the most common type of congenital vascular anomaly
and may cause significant morbidity and pain.1 While surgery has historically been
useful in the management of VMs, percutaneous sclerotherapy has become standard
treatment for VMs, requiring less operative time and associated with less blood loss per
lesion volume compared to surgery.2, 3 Percutaneous sclerotherapy has a technical
success rate ranging between 71 and 100% depending on lesion location, volume, and
operator experience4, with complete relief of symptoms in 27-68% of patients and
overall response of 67-100%.5 For patients experiencing persistent symptoms after
sclerotherapy, and for select patients for which a multidisciplinary committee has
deemed alternative primary treatments appropriate, percutaneous cryoablation has
shown to serve as a potential treatment option.6, 7 However, there are limited
prospective studies evaluating the safety and efficacy of cryoablation in venous
malformations.

Statement of Purpose
In this study, we perform a systematic review of percutaneous cryoablation for VMs in
regards to safety, technical success, clinical response, and adverse events.
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Epidemiology
Venous malformations are vascular anomalies comprised of ectatic venous channels
found most commonly in the limbs, trunk, head, and neck.8 Venous malformations are
present at birth and typically grow without spontaneous regression, however they are
often not clinically evident until later in life when the patient stops growing. 9 The
incidence of venous malformations is between 1/5000 and 1/10000 births and is the
most common vascular anomaly seen in referral centers.10

Genetics
While venous malformations are most commonly sporadic, patients with suspected
familial inheritance have been studied for genetic patterns. A gene on the short arm of
chromosome 9 was the first locus found to be linked to the venous malformation
phenotype.11 Subsequent studies of different families with inherited venous
malformations demonstrated genetic linkage to the same region on chromosome 9. 10
The first study utilizing positional cloning and candidate gene analyses for venous
malformations demonstrated that two families with inherited venous malformations
had a mutation in the gene encoding the angiopoietin receptor, endothelial specific
receptor tyrosine kinase TIE2, specifically discovering a single amino acid substitution at
R849W, affecting the intracellular kinase domain.12 This finding was supported by
subsequent studies that identified additional loss-of-function mutations in the
angiopoietin receptor gene TIE2/TEK.13
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In later studies, patients with venous malformations have been discovered to have
upregulation of tissue growth factor beta (TGF-beta) and basic fibroblast growth factor
(beta-FGF).14 Additionally, progesterone receptors have been identified in venous
malformations, which helps explain the clinical observation that venous malformations
tend to grow more rapidly during hormonal changes, such as puberty, pregnancy, and
use of oral contraceptive pills.15

As genetic studies continued to be performed, venous malformations were found to be
associated with other genetic loci and therefore multiple genetic syndromes. The
International Society of the Study of Vascular Anomalies (ISSVA) has compiled lists of
these associated syndromes and their causal genes. Awareness of these associated
syndromes can help physicians identify need for further workup in patients presenting
with venous malformations.

Notable syndromes linked to the TIE2/TEK gene include Blue Rubber Bleb Nevus
Syndrome (BRBNS, or Bean’s syndrome) and Multiple Cutaneous and Mucosal Venous
Malformations syndrome (VMCM).16 BRBNS presents with multifocal venous
malformations of the skin and gastrointestinal tract. Skin lesions are typically the first
manifestations identified clinically, and appear as rubbery, dark-blue venous nodules or
as skin-colored compressible protuberances.17 These patients are prone to developing
anemia due to chronic GI bleeding, and therefore require lifelong iron and blood
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transfusions18. In rare cases, central nervous system manifestations are seen late in
disease progression, where compression from venous malformations in the brain can
lead to seizures and focal neurological deficits.17 VMCM is an autosomal dominant
syndrome that presents with small, multifocal bluish cutaneous and mucosal venous
malformations. While new lesions appear over time, lesions are typically present at
birth. These venous malformations are usually small and asymptomatic, although larger
lesions can invade subcutaneous muscle and cause pain. 19

PIK3CA-related overgrowth spectrum (PROS) includes a variety of heterogenous
overgrowth phenotypes due to somatic PIK3CA activating mutations. Two notable PROS
syndromes that include vascular malformations are CLOVES syndrome (Congenital
Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, Scoliosis/Skeletal and
Spinal) and Klippel-Trenaunay syndrome (KTS).16 KTS presents with capillary
malformations, venous malformations, limb overgrowth, and may or may not include
lymphatic malformations. Clinically, KTS presents with a triad of extremity varicosities,
cutaneous vascular malformations (often a port-wine stain), and hypertrophy of soft
tissues and long bones, which may cause pain, edema, ulcerations, and pruritis. 20, 21

Other genetic syndromes associated with venous malformations include ServelleMortorell syndrome, which presents with limb venous malformations and bone
undergrowth, Maffucci syndrome, which is associated with the IDH1/IDH2 gene and
may present with spindle-cell hemangiomas and enchondromas, Proteus syndrome,
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which is associated with the AKT1 gene and presents capillary malformations and
asymmetrical somatic growth, and Bannayan-Riley-Ruvalcaba syndrome, which is
associated with the PTEN gene and presents with AVMs, macrocephaly, and lipomatous
overgrowth.16

Clinical Presentation
The classic presentation of venous malformations includes chronic extremity pain and
swelling that is worsened in the dependent position and early mornings (secondary to
blood-pooling). Episodes of acute pain are common, secondary to micro-thrombosis,
and may improve with non-steroidal anti-inflammatory medications (NSAIDs). For the
purposes of documenting treatment response, most institutions assess an overall preand post- treatment pain score. Out of 54 patients reviewed, all but one patient
presented with pain.

The average patient age was 35.5 years old and 71.0% of patients were female. Lesion
location was reported in 51 out of 55 cases, with the most common lesion location
being in the lower extremities (36 cases, 70.6%), followed by the upper extremities (7
cases, 13.7%), thoracic wall (4 cases, 7.8%) and abdominal wall (4 cases, 7.8%).
Intramuscular versus extra muscular location was reported in 37 cases, with 34 cases
being intramuscular 91.9%. Prior sclerotherapy treatment was noted in 31 of 54 patients
(57.4%), including six patients with multiple treatments (11.1%). Prior surgeries were
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noted in seven patients (13.0%). Table 2 summarized prior treatments. The initial pain
scores in patients with previous sclerotherapy treatments was 4.7, compared to 5.0 in
patients with prior surgery, and 5.8 in patients without prior sclerotherapy or surgery.

Classification of Vascular Anomalies
The International Society for the Study of Vascular Anomalies (ISSVA) has established a
classification system which utilizes pathologic and hemodynamic features of vascular
anomalies to categorize them.16, 22 When using the ISSVA system, congenital vascular
anomalies are first determined to be either vascular tumors or vascular malformations.
This distinction is critical as many vascular malformations are misdiagnosed as
hemangiomas, the most common vascular tumor.23 One study reports that up to 71.3%
of hemangioma cases are misclassified, leading to suboptimal medical management in
up to 20.6% of those diagnosed with a hemangioma.24 Vascular tumors, such as
hemangiomas, will demonstrate evidence of mitosis in endothelial cells on
histopathology, confirming increased endothelial cell turnover. Vascular malformations,
on the other hand, will demonstrate structural abnormalities of the vasculature or
lymphatic system on histopathology, without evidence for increased endothelial cell
turnover.25

Once the lesion has been determined to be a vascular malformation as opposed to a
vascular tumor, imaging may be used to help further differentiate types of vascular
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malformations. Ultrasound is used to determine if the lesion is a low-flow vascular
malformation, which suggests capillary, venous, or lymphatic components, versus highflow vascular malformation, which suggests arterial components.25

Ultrasound can further differentiate the type of low-flow vascular malformation by
considering if the lesion appears cystic, indicating a mostly lymphatic lesion, versus if
the lesion appears solid, indicating a mostly venous lesion. MRI is primarily used for
evaluation of lesion extent and to help the medical team create a treatment plan. 25
Additional details regarding the diagnosis of venous malformations can be found in the
Diagnosis of Venous Malformations section below.

Diagnosis of Venous Malformations
The diagnosis of a venous malformation was made with imaging, with all studies utilizing
ultrasound and MRI, and biopsy in three of the eight studies (17 of 55 cases, 30.9%) 26-28.
The exact imaging criteria utilized in these studies was somewhat heterogenous and not
clearly defined in all papers. This is further discussed in the limitations section. However,
in general on sonography venous malformations appear as tubular, compressible,
structures with internal flow. Spectral doppler is used to confirm venous flow and
exclude the presence of arterial wave forms which may suggest an arteriovenous
component. On MRI, VM typically appear as homogenous tubular or cystic T2 bright
structures which may be focal or diffusely infiltrative. Examples of venous
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malformations obtained from the authors’ institution is included in Figures 2 and 3. On
occasion, imaging presentation may be atypical and features can overlap with FibroAdipose Vascular Anomalies (FAVA). In these circumstances biopsy is helpful to confirm
the diagnosis.

Morphologically, venous malformations may appear focal and “mass-like”. However, on
T1 they will appear more spongy or cavernous, as opposed to vascular tumors which will
appear as well circumscribed solid masses. Alternatively, venous malformations may be
diffuse at times with impressive invasion of the various tissue planes. This may on
occasion mimic the infiltrative nature of an arteriovenous malformation (AVM), which
can be differentiated with ultrasound. Lastly, T2 signal voids in venous malformations
are often seen due to the presence of phleboliths. This can be differentiated from the
flow-voids seen in AVMs and hemangiomas on susceptibility weighting imaging (SWI) or
Gradient Echo Imaging (GRE). If available, radiographs can also confirm the presence of
phleboliths. Of course, the lack of phleboliths does not exclude the presence of a venous
malformation.

When performed with contrast, venous malformations tend to fill heterogeneously due
to the variations in flow. Special note should be made of large draining veins, as this
helps plan sclerotherapy technique. On occasion, computed tomography (CT) can be
helpful to evaluate the adjacent bony structures, as venous malformations can lead to
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bony remodeling and tissue hypertrophy (though less significantly than AVMs) (Figure
3).

Standard of Care and Alternative Therapies
Patients with symptomatic venous malformations are frequently referred for treatment
by interventional radiologists, however, a multidisciplinary approach is necessary to
determine if treatment is likely to be successful. Consultation with dermatologists,
surgeons, and other specialists can help design a complete treatment regimen specific
to patient concerns.1 Venous malformations of the limbs usually present with worse
symptoms and higher recurrence than truncular venous malformations, and therefore
are more likely to require treatment.29 Indications for treatment of venous
malformations includes disabling pain, functional impairment, bleeding (including
subdermal, intramuscular, or retroperitoneal hematomas, hematuria, rectal bleeding,
hematemesis, hemoptysis, and intracerebral or intraspinal bleeding), lesions that are in
close anatomical proximity to important structures or vessels, lesions in areas with high
probabilities of complications, lesions with ultrasound evidence revealing excessively
adverse hemodynamic effects, excessive cosmetic implications, and recurrent
thrombosis.1

Larger venous malformations are associated with consumptive coagulopathies such as
localized intravascular coagulation (LIC), which is characterized by elevated D-dimer and
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decreased fibrinogen levels.30 LIC causes localized pain and thrombosis within a lesion,
and can lead to further hemorrhagic or thrombotic complications, such as severe
bleeding during surgery or in the event of trauma.31 LIC is primarily managed with lowmolecular-weight-heparin (LMWH) and other anticoagulation in order to prevent
decompensation to disseminated intravascular coagulopathy (DIC).31, 32

When immediate treatment of a venous malformation is not required, it is important to
manage complications such as pain or anemia caused by bleeding. Compression
stockings can be used in patients with venous malformations in the extremities to force
venous blood out of stagnant venous malformations, thereby reducing swelling and risk
for thrombophlebitis. Pain may also be managed with daily aspirin-81, although there
are limited studies evaluating the efficacy of this management strategy.33

When definitive treatment of a venous malformation is indicated, treatment strategies
may include surgery, sclerotherapy, ablative techniques, or a combination of the
aforementioned therapies. Surgical intervention is considered when the lesion is
anticipated to be able to be completely resected with minimal anatomic or functional
complications. Truncular venous malformations are most amenable to surgery as they
are typically large and localized. Additionally, they have minimal chance of recurrence
post-resection due to their embryonic nature. Surgery for truncular venous
malformations may or may not include adjunct sclerotherapy or N-butyl cyanoacrylate
(nBCA) injections 24-48 hours prior to excision.9 Venous malformations of the
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extremities are less amenable to surgery as they are often more complex and diffusely
infiltrative lesions, often involving multiple layers of fascia and muscle. This lesion
complexity increases risk for secondary intraoperative bleeding and increases chance of
recurrence.9 Instead, venous malformations of the extremities are often treated with
sclerotherapy, a more cost-effective alternative that greatly decreases risk of bleeding
due to the use of minimally invasive techniques.29

Ethanol sclerotherapy is the most common sclerosant used to treat venous
malformations. Ethanol denudes endothelial cells from the venous walls and cause
fractures at the level of the internal elastic lamina. Treated tissue undergoes necrosis
and apoptosis, leading to platelet aggregation, intravascular thrombosis, and a painful
inflammatory response that requires general anesthesia.34, 35 In a systematic review of
sclerosing agents for vascular malformations of the head and neck, ethanol
complications are observed in up to 18% of cases and may include collateral tissue or
skin necrosis, nerve damage, paresthesias, vascular spasms, ischemia, acidosis,
hypoglycemia, and secondary intravascular hemolysis.1, 36 Other sclerosants such as
pingyangmycin, OK-432, ethanolamine oleate, bleomycin, polidocanol, doxycycline, and
sodium tetradecyl sulfate (STS) have complication rates between 0-6%, but are more
expensive and have not yet been proven to be superior to ethanol in terms of treatment
success. All of these sclerosants, including ethanol, have response rates between 71100%, although the authors of the systematic review cite high rates of bias in their
source data.36
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Endovenous laser and radiofrequency ablation therapies have been used in cases where
surgery or sclerosants have shown limited success. These therapies have been used
primarily in patients with truncular venous malformations experiencing symptomatic
venous insufficiency of the lower extremities. These techniques relieve symptoms by
ablating incompetent venous reflux channels.3 One study utilizing ultrasound-guided
endovenous diode laser therapy for venous malformations found a 100% success rate
for treatment symptoms of pain and activity limitation, but a final clinical success rate of
63% when including residual swelling and cosmetic complaints. 37

This systematic review focuses on the use of cryoablation for venous malformations,
evaluating treatment efficacy in terms of reduction of pain and lesion size, as well as the
risk for complications. Treatment plans vary widely between institutions, operator
experience, and patient needs. Due to considerations of cost to the patient,
complications, and potential need for additional treatment, we emphasize the
importance of creating a treatment plan as a part of a multidisciplinary team.

Representative Case Report
This systematic review contains data from one case report, which details the clinical
presentation, treatment, and outcome for a patient who undergoes cryoablation for a
venous malformation. We will review the details from this case report to demonstrate a
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patient experience from the diagnosis of their venous malformation through definitive
treatment with cryoablation.

Case Report: Amin et al. (2018)
In this case, a 35-year-old woman presented with pain in the right leg. Ultrasound and
MRI suggested a 1.5 cm venous malformation in the right vastus lateralis muscle may
the causal lesion, and biopsy of the lesion confirmed the diagnosis of venous
malformation.38 As discussed in the Classification of Vascular Anomalies section above,
the use of ultrasound and MRI is ideal for the diagnosis of venous malformations,
however, the use of biopsy to confirm the lesion identity on histopathology can be
important if there is concern that the lesion may be confused with a vascular tumor,
such as a hemangioma.25

As a first-line attempt to manage the patient’s leg pain, nonsteroidal anti-inflammatory
drugs (NSAIDs) were given. When conservative pain management provided minimal
relief, the patient was offered sclerotherapy treatment.38 Despite the use of NSAIDs as
the standard of care for a patient who is newly diagnosed with a painful venous
malformation, Nguyen et al. discusses the limited data supporting the efficacy of this
conservative management strategy.33 The patient underwent multiple attempts at
sclerotherapy but the lesion persisted on imaging and the patient continued to report
pain scores as high as 9 out of 10. It was then decided by the care providing team to
attempt cryoablation of the lesion.38
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Utilizing computed tomography and ultrasound for needle guidance, a cryoprobe was
inserted percutaneously over the lateral distal thigh, overlying the venous
malformation. The procedure was performed with local anesthesia only. Hydro
dissection of tissue was performed before cryoablation of the venous malformation
began. To hydro dissect, normal saline was injected into the subcutaneous tissue
superficial to the venous malformation.

The use of hydro dissection in this case was cited for protection of the surrounding skin
and fascial layers from damage during freezing cycles which are intended to target the
intramuscular lesion only.38 Hydro dissection is only used in 4 of the 52 cases in this
systematic review, when operators determined that structures within 5 mm of the
target lesion, such as surrounding nerves, muscle, fascia, or skin may be damaged by the
ice ball. 7, 27, 28 39 There were not enough cases with detailed outcome data in this series
to determine with statistical significance if hydro dissection providers a better safety
profile in terms of reduced complications.

Once the tip of the cryoprobe was placed within the lesion on imaging, cryoablation was
performed. This case used two freezing cycles, one 7 minutes and one 9 minutes, with
12 minutes of passive thawing in-between. The cryoprobe was removed after a final
round of passive thawing.38 The total freeze time in this case was 16 minutes, which is
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lower than the mean total freeze time of 20.9 minutes amongst the 28 cases in this
systematic review that detailed freeze times.7, 26, 40, 27

Computer tomography and ultrasound were used to confirm that the ice ball
encapsulated the lesion, and a final ultrasound demonstrated no evidence of hematoma
formation during the procedure.38 Evaluating for hematomas is important in all
interventional radiology procedures, as a large hematoma is at risk for infection or
pocket dehiscence.41 In rare cases, very large hematomas have been shown to lead to
hypovolemic shock in the patient.42 In the event of that a hematoma is identified and
raises concern for these dangerous sequelae, it is recommended to immediately
evacuate the hematoma.41 While hematomas are an important complication to be
aware of, interventional radiology procedures are far less likely to cause bleeding when
compared to surgery for the treatment of venous malformations. 1 One article from this
systematic review reports a case where a minor hematoma was identified postprocedure. This hematoma resolved without further complications.28

8 months after the patient underwent cryotherapy for their venous malformation, the
patient was evaluated in a follow-up visit. The patient reported no residual pain or
recurrence of symptoms.38 This complete resolution of patient symptoms is especially
impressive as the patient had undergone multiple sessions of sclerotherapy and had
continued to report pain scores as high as 9 out of 10. As is later detailed in the Results
section of this systematic review, our analysis demonstrates that 20 of the 31
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cryoablation patients (64.5%) which report pre- and post- procedure pain data reported
no residual pain at final follow-up.
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MATERIALS AND METHODS

Student Contributions
Literature search, study selection, data extraction, and organization of data were
performed by Alexander Moushey. The Diagnosis of Venous Malformations section was
written by Adam Fish, MD. Discussion and Limitations sections were originally written by
Adam Fish, MD and expanded upon by Alexander Moushey. Statistical analysis was
performed by Lawrence Staib, PhD, Professor of Radiology and Biomedical Imaging at
Yale School of Medicine. Mentorship and thesis review was provided by Todd
Schlachter, MD, Assistant Professor of Radiology and Biomedical Imaging at Yale School
of Medicine.

Search Strategy
An electronic-based literature search for clinical studies utilizing percutaneous
cryoablation of VMs was performed in PubMed and Google Scholar using the following
terms or combinations of terms: “cryoablation”, “percutaneous cryoablation”, “venous
malformation”, and “low flow vascular malformation”. The search was limited to human
trials up to July 2021. Titles and abstracts were screened to identify relevant articles,
and references within relevant articles were manually reviewed. An IRB was not
required for systematic literature review.
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Study Selection Criteria
All retrospective reviews, prospective non-randomized studies, and case reports related
to primary or secondary treatment of venous malformations with percutaneous
cryoablation were included for review. Articles were excluded if they did not describe
the technical approach or specific outcomes listed below. VM cases within these
selected studies were then evaluated by: (1) patient characteristics (age, sex, method of
diagnosis); (2) indication for cryoablation (symptoms, prior treatments); (3) cryoablation
technique (number and timing of freezing cycles); (4) technical success rate; (5) followup (clinical success rate, morbidity, and change in lesion size on post-procedure
imaging); and (6) requirement for additional procedures or medical management.
Amongst selected articles, patients were excluded if their treated lesions were
diagnosed as FAVA or hemangioendothelioma, or if the VM was treated with
interventions other than cryoablation. The studies were selected and evaluated by two
authors (A.M. and A.F.). Patient selection flow-chart is diagramed in Figure 1.

Data Extraction
The review was performed following the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines. Study characteristics are
demonstrated in Table 1. In order to study the safety of the cryoablation procedure, all
studies identified were included in the safety analysis. Adverse events were graded
according to the Society of Interventional Radiology (SIR) classification system 43.
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Aggregates of treatment techniques were recorded, including number and timing of
freeze cycles. Note was made of whether or not patients had previously received
sclerotherapy or whether cryoablation was used as a first-line treatment option. Table 2
demonstrates a summary of the associated clinical history. In order to reduce
heterogeneity in assessing treatment outcomes, only cases with pre and post
procedural pain scores (scored 1-10) and volume measurements were included for
variable analysis. Pain scales included the visual analog scale (VAS) and numerical pain
rating scale (NPRS)44.

Study Risk Bias
Analysis of the methodologic quality of the studies included in this systematic review
was performed utilizing a modified version of the Newcastle-Ottawa Quality Assessment
Scale (NOS). This tool is designed for use in Case Control studies, so modification was
necessary to assess risk of bias in selected studies that do not include a control group.
We focused on the following questions from the NOS tool: 1) Is the case definition
adequate, with clearly defined inclusion and exclusion criteria for patient selection? 2)
Were procedures clearly detailed? 3) Was clinical follow-up satisfactory? and 4) Were
outcomes clearly reported? Table 3 summarizes the heterogeneity of the selected
papers and Table 4 demonstrates the NOS scores.
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Data Analysis
A quantitative meta-analysis was performed for pre- and post-procedural change of
volume and change of pain. Heterogeneity, measured by Higgins I 2. Due to the relatively
small sample sizes, stratified variable analysis such as history of sclerotherapy, freezing
times, and initial lesion volume were unable to be performed. Averages for pre- and
post- pain scores for the sclerotherapy group were calculated.
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RESULTS

Literature Search
The initial literature search yielded 73 articles. We excluded 59 articles upon review of
the abstracts and titles. 14 articles were selected for full-text screening, of which 8 met
inclusion criteria. The remaining 6 articles were excluded for reasons including 1) noncryoablation interventions performed (4 articles) and 2) use of unclear terminology
making it difficult to determine if the treated lesions were VMs, hemangiomas, or
lymphatic malformations and limited outcomes reporting (2 articles). Between the 8
studies included, a total of 67 patients were available for data analysis. A total 54 of the
patients, with 55 VMs, met inclusion criteria as their lesion was a VM and was treated by
cryoablation. The remaining 13 patients were excluded for reasons including 1) the
treated lesion was identified as FAVA (6 patients), 2) the treated lesion was identified as
hemangioendothelioma (2 patients), and 3) alternative therapies were used and thus
cryoablation was not attempted to treat the VM (5 patients).

Characteristics of Included Studies
A summary of the study characteristics used in this systematic review is included in
Table 1. After critical evaluation of clinical studies detailing treatment of venous
malformations with cryoablation, eight articles fit inclusion criteria listed above and are
included in cumulative data analysis. Six articles are retrospective reviews 6, 7, 26, 40, 39, 27,
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one article is a case report38, and one article is a prospective non-randomized trial.28 The
cumulative data comprised of 54 patients (55 total cases) with a mean age of 35.2 years
(range of 10-71). Of the 55 venous malformation cases, 21 cases (38.2%) had no prior
treatment and 31 cases (56.2%) had prior sclerotherapy which did not completely
resolve patient symptoms. Treatment history for venous malformations is summarized
in Table 2.

Treatment Technique
Cryoablation technique varied between the articles reviewed, in part due to the
variability in size and location and in part due to the lack of unified treatment regimen.
The most common treatment regimen employed was with general anesthesia, CT
guidance, and two ten-minute freeze cycles per cryoprobe. CT guidance was employed
in 36 cases (65.5%), US guidance in 14 cases (25.5%) and MRI in 5 cases (9.0%). Of the 52
cases which reported the number of freeze cycles utilized, 51 cases required two freeze
cycles and only one case required four freeze cycles. Freeze times were reported in 28
cases with a mean total freeze time of 20.9 minutes.7, 26, 40, 27 The median number of
cryoprobes used per case were 2 (range 1-10). Additional methods employed included
hydro dissection (used in 4 cases) for peripheral lesions with less than <1cm of overlying
subcutaneous tissue.7, 27, 28 39 Technical success, as defined by the ice ball covering the
entire lesion, was achieved in 54 of 55 cases.
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Procedural Outcomes
Volume change:
Random effects analysis performed included three studies (27 cases) which provided
quantitative results allowing for pooled analysis.26-28 Amongst the 27 cases, preprocedure lesion volume averaged 24.6 mL (median of 6.1 mL, range of 0.62 to 155.6).
An overall volume decrease of 21.96 cc (95% CI 3.08 – 40.90) which corresponds with a
weighted mean decrease of 92% (raw mean of 71.7%, median of 83.5%, range -17.6% to
100%). Heterogeneity, measured by Higgins I2, was not found to be significant (I2 = 44%,
p = 0.17). Mean follow-up time was 27 months (median of 6 months, range of 6 to 78
months). A random effects model (Figure 4a) and funnel plot (Figure 4b) demonstrate
the effect size for each study included in the weighted mean.

Pain score change:
Five of the eight studies, 31 of 55 cases, reported pain associated with the lesion preprocedure and post-procedure. To quantify pain, three articles used VAS 26-28, one article
used NPRS7, and one case report used self-reported numerical score 38, all of which rank
pain between 0 and 10 with a score of 0 indicating no pain and a score of 10 being the
most severe.
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The initial pain scores in patients with previous sclerotherapy treatments was 4.7,
compared to 5.0 in patients with prior surgery, and 5.8 in patients without prior
sclerotherapy or surgery.

Random effects analysis included two studies (23 cases) which provided quantitative
results allowing for pooled analysis. An overall decrease in pain of 3.84 (95% CI 1.71 –
5.98) was found which corresponded with a weighted mean decrease of 77%.
Heterogeneity, was not found to be significant (I2 = 58%, p = 0.12). A random effects
model (Figure 5a) and funnel plot (Figure 5b) demonstrate the effect size for each study
included in the pain score weighted mean. When including all studies that provided preand post-procedural pain scores, including Cornelis 201345 which provided mean pain
scores (without individual results), and Autrusseau 2020 46, which used NPRS pain scores,
a non-weighted mean reduction in pain score was 78.2% +/- 42.8%) across the 31 cases.
20 of 31 cases (64.5%) reported complete resolution of symptoms with no residual pain.

Three articles that did not quantify pre- vs post-procedural change chose to report pain
outcomes in different ways. Thompson et al report complete resolution of pain in two
out of three venous malformation cases (66.7%), with the remaining case recording a
residual moderate pain at 3-month follow-up, later requiring laser therapy treatment
which resulted in complete resolution of symptoms.6 Ramaswamy et al report complete
resolution of pain in seven of nine cases (77.8%) with the remaining two patients
reporting residual pain at final follow-up.39 Carabin et al report complete relief of
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symptoms in 6 of 11 patients (54.5%) who completed follow-up. 4 of 11 (36.3%)
reported partial relief, and 1 of 11 (9.1%) reported no improvement. 40

When including all cases that had pain evaluated at final follow-up, complete resolution
of pain was seen in 35 of 55 cases (63.6%) and overall (complete or partial)
improvement of pain was seen in 52 of 55 cases (94.5%).

Adverse Events
Hospital stays ranged from 0 to 3 days across all studies, with 17 of the 55 procedures
being performed outpatient (30.1%). Rationale for hospital stay was provided in a few
studies, citing desire to monitor for neurovascular injury. Immediately post-procedure,
pain was reported in 18 cases (33.3%), swelling in 10 cases (18.5%), and numbness or
dysesthesia in seven cases (13.0%). These symptoms were transient for most patients,
lasting under two weeks. There were two major adverse events (3.7%), with both cases
due to continued numbness or dysesthesia at their final follow-up, one experiencing
sciatic paralysis.

Cornelis et al. notes that the patient with sciatic paralysis was included in their study
inappropriately, as the sciatic nerve was less than 5 mm away from the treated lesion, at
the limit of their eligibility criteria.28 This patient had partial recovery at 6 months.28 In
order to avoid nerve complications, Cornelis et al. proposes extensive protective
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dissection with saline or CO2 if critical structures are closer than 5 mm to the targeted
lesion. They also propose performing cryoablation under local anesthesia or conscious
sedation to allow for direct patient feedback in the event that nerve damage is
perceived.28

There were four cases of minor adverse events not related to pain (7.4%), include two
cases reporting skin blisters that resolved within two weeks39, one minor hematoma,
and one small myositis treated medically without complication. 28 There were zero cases
(0.0%) resulting in death, life-threatening complications, or escalation in care.
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DISCUSSION

Cryoablation for venous malformations is a novel and potentially promising treatment
option. However, prospective studies evaluating the efficacy and safety are limited. To
address this issue, we performed a systematic review of eight studies, consisting of 54
patients, in which venous malformations were treated with cryoablation.

Cryoablation was shown to be effective in reducing volume size and pain. There were
three studies which included pre- and post-procedural volumes, including 27 cases,
which allowed for pooled analysis. These three studies demonstrated insignificant
heterogeneity as measured by Higgins I2. A total of five studies, including 31 patients,
provided pre- and post-procedural pain scores, allowing for unweighted averaging of
pain score changes. Of these studies, only two studies, including 23 cases, met criteria
allowing for pooled analysis. Pooled analysis of these two studies demonstrated
insignificant heterogeneity as measured by Higgins I2. It is worth noting that the
difference between the weighted and non-weighted mean decrease in pain-scores was
very small (77% and 78.2% respectively; difference of 1.2%).

The issue of pre-procedural sclerotherapy is undoubtably an important one. However,
due to the small populations, pooled variable analysis was not able to be performed.
Therefore, non-weighted averages were calculated. The initial and post-treatment pain
scores for the sclerotherapy group were smaller (4.7 and 1.3, compared with 5.0 and 3.3
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with prior surgery and 5.8 and 2.8 with no prior treatment). This may suggest a benefit
of sclerotherapy prior to cryoablation. Additionally, the benefit of sclerotherapy is likely
underestimated by the selection bias of choosing lesions that did not demonstrate
complete resolution to sclerotherapy.

Adverse events were documented and analyzed for all 54 patients. Cryoablation of
venous malformations were found to be generally safe, though additional studies are
needed. Known complications of cryoablation generally include hemorrhage, abscess
and non-target tissue damage.47 There were four cases of minor adverse events (9.3%),
including temporary blistering, self-resolving hematoma and myositis treated
pharmacologically. There were two major adverse events (3.7%) due to persistent
dysesthesia at the time of final follow-up. These events may be avoidable by limiting iceball margins to greater than 5mm or by employing the use of neuromonitoring. There
were no cases resulting in death, life-threatening morbidity, or escalation in care.

Limitations
There are significant limitations in this study due to the small patient population and
heterogeneity of the included studies, which are primarily retrospective. There were no
set standards for diagnosing a venous malformation. In three of the eight studies (17 of
55 patients, 30.9%) biopsies were utilized to confirm the diagnosis, with five studies
relying on imaging a lone. Though, biopsy is not typically necessary to confirm the
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diagnosis48, in some instances biopsy or venography is necessary to differentiate
between diffusely infiltrative VMs and FAVAs49. Of note, 29 of the 38 patients (76.3%)
that were not biopsied, had sclerotherapy and could presumably be diagnosed by
venography, however this was not specifically discussed in the papers. While six patients
were identified as having FAVAs and therefore excluded from the study, it is possible
that some of the larger VMs that were not biopsied may have been diagnosed. This may
pose as a confounding factor as a growing body of literature has demonstrated the
efficacy of cryoablation in FAVAs49, 50.

Another important potential confounding factor was the lesion size. The median lesion
size of 6.1 mL compared to the average of 24.6 mL is considerably smaller, which
suggests significant selection bias that may overestimate the efficacy of cryoablation
compared to other standards of treatment. However, this may also suggest that smaller,
more focal lesions are better candidates for cryoablation. Considering the reduced posttreatment scores of the sclerotherapy group, it may be that a combined regimen of
sclerotherapy and cryoablation for smaller, more focal lesions is optimal. Future
randomized trials should be performed comparing sclerotherapy and cryoablation,
including treatment groups with sclerotherapy and cryoablation, sclerotherapy alone
and cryoablation alone.

An additional challenge of the study is in uniformly evaluating pain. In order to mitigate
this issue, only studies using a 1-10 pain scale before and after the procedure were
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included in assessing changes in pain. Furthermore, changes in pain were compared
alongside changes in volume, which were found to be similar.

The different pain scales used include the visual analog scale (VAS), the numerical pain
rating scale (NPRS), and a self-reported numerical score from 1-10. The VAS is a scale
consisting of a 10 cm long horizontal line with end points of “no pain” and “worst
possible pain”. The patient marks a point on the scale to communicate their pain level.
The NPRS is a verbal scale where the patient is asked to rate their pain from 0 (“no
pain”) to 10 (“worst possible pain”). Many studies evaluating the differences in data
collected between VAS and NPRS systems found their respective scores to be strongly
correlated with one another.51, 52 In a study evaluating patients with chronic low back
pain, severe disability can be predicted with a score of 6 in VAS or NPRS, while moderate
disability can be predicted with a VAS score of 4 or an NPRS score of 3. 52 While these
slight differences in pain scales may affect documentation of the true qualitative pain or
disability experienced by a patient, this systematic review evaluates pre- vs postprocedure change in pain, as opposed to a post-procedure pain score alone.

An additional obstacle in the evaluation of change in pain or change in lesion volume is
due to the large variability in follow-up times between studies. Fujiwara et al. collected
pain data at three time points: before cryoablation, 12 months after the procedure, and
a final follow-up 4-7 years after the procedure.27 To contrast, Cornelis et al. collected
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pain data at three different time points: before cryoablation, 7 days after the procedure,
and a final follow-up 6 months after the procedure.28

Cryotherapy technique varied widely (or was sparsely reported) from study to study and
likely played a role in treatment outcomes. While most studies utilized two freeze
cycles, freezing time per cycle ranged from 6.3 to 40 minutes.40, 27 Thawing times
between freeze cycles were not reported in every study. Additionally, some studies
utilized hydro dissection to separate nearby tissues from target freezing areas, with the
goal of reducing the rate of complications.

Lastly, this study found a significantly increased improvement in pain reduction in
females when compared to males. While this may be valid, this conclusion is limited due
to the small population of males and subjectivity in pain scores. Larger studies are
needed to confirm this finding.
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CONCLUSION

Cryoablation of venous malformations is potentially safe and effective for select
patients. Additional prospective studies with clear diagnostic criteria including possible
biopsies to exclude FAVAs and longer follow-up time periods are needed to further
investigate this treatment option.
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FIGURES
Figure 1: Study Selection

Figure 1 – A flow chart demonstrates the study selection process.
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Figures 2 and 3 – Images from author’s institution demonstrating example lesions (not
included in the study).

Figure 2 - A sagittal STIR (left) demonstrates a T2 intense cavernous/spongy lesion within the posterior
thoracic muscles. Sagittal CT of the same patient demonstrates small phleboliths (arrows).
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Figure 3- Grayscale and color ultrasound (top images) demonstrating infiltrative cavernous hypoechoic
lesion made up of dysplastic vessels. STIR axial (bottom left) and coronal (bottom right) from the same
patient demonstrates T2 hyperintense infiltrative lesion within the anterior, lateral and posterior
compartments of the thigh.

Figures 4a and 4b: Volume change random effects model and Funnel plot

Standardized Mean Difference

Figure (4a) - Random effects model calculating the standardized mean difference. This corresponded with
a weighted mean decrease of 29.66cc or 92%. Figure (4b) - A funnel plot demonstrates the effects
estimates from each study.
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Figures 5a and 5b: Pain score random effects model and Funnel plot

Funnel Plot

Figure 5a - Random effects model calculating the standardized mean difference of pre- and postprocedural pain score changes. This corresponded with a weighted mean decrease of 3.84 (CI 1.71 – 5.98)
or 77%. Figure (5b) - A funnel plot demonstrates the effects estimates from both studies.
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Table 1: Study Characteristics

Averag
e age
(years)

Patients
(n)

Sex
(male
%)

Prior
sclerotherapy (%)

Initial
lesion
volume
median
(mL)

Volume
decrease
at final
followup (%)

Initial
pain
score
median
(1-10)

Pain
score
decrease
at final
followup (%)

Average
followup time
period
(mo)

Author

Year

State

Design

Fujiwara et
al.

2021

Japan

Retrospective
review

9

36.6

22.20%

66.67%

2.49

83.40%

7

80.74%

69.1

Autrusseau
et al.

2020

France

Retrospective
review

3

40

33.30%

0%

35

Not
included

6

Not
included

23.2

Thompson
et al.

2015

USA

Retrospective
review

3

27.3

66.70%

100%

Not
Included

Not
included

Not
included

N/A

5.3

Cornelis et
al.

2013

France

Retrospective
review

4

41.8

0%

50%

49

95.00%

5

100.0%

6.5

Ramaswam
y et al.

2019

USA

Retrospective
review

8

30.3

54.5%*

75%

10.96

Not
included

Not
included

Not
included

6.0

Carabin et
al.

2020

France

Retrospective
review

12

42

58.30%

0%

32.5

90.77%

7

86%

14.8

Amin et al.

2018

USA

Case Report

1

35

0%

100%

Not
Included

Not
included

9

100%

8.0

Cornelis et
al.

2017

France

Prospective
nonrandomized
trial

14

30.3

35.70%

92.86%

5.55

57.55%

4

64.05

6.0

Table 1 – Summary of study characteristics.
* 54.5% of the 11 patients in the study are male, however 3 of the patients had FAVA and were excluded
from the study. Sex distribution of the remaining 8 patients is unknown.

Table 2: Associated clinical history
Associated clinical history for VMs
Prior sclerotherapy
Prior sclerotherapy (x2 or more)
Prior surgery
Prior surgery and sclerotherapy
Any previous treatment (sclerotherapy or
surgery)
No previous treatment
Table 2 – Summary of associated clinical features.

Number (%)
31 (57.4)
6 (11.1)
7 (13.0)
4 (7.4)
34 (63.0)
21 (38.9)
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Table 3: Study Heterogeneity

Study

Author

Year

Study

Study

included at

Study

Study

included

included

least one

included

included

Average

Sex

how lesion

total

follow-up

change in

change

Patients

age

(male

was

freezing

(5 months

lesion

in pain

(n)

(years)

%)

diagnosed

time used

or longer)

volume

score

Fujiwara et
al.

2021

9

36.6

22.2%

Yes

Yes

Yes

Yes

Yes

2020

3

40

33.3%

Yes

Yes

Yes

No

Yes

2015

3

27.3

66.7%

Yes

No

Yes

No

No

2013

4

41.8

0%

Yes

Yes

Yes

Yes

Yes

2019

8

30.3

54.5%*

Yes

Yes

No

No

No

al.

2020

12

42

58.3%

Yes

Yes

Yes

No

No

Amin et al.

2018

1

35

0%

Yes

Yes

Yes

No

Yes

2017

14

30.3

35.7%

Yes

No

Yes

Yes

Yes

Autrusseau
et al.
Thompson
et al.
Cornelis et
al.
Ramaswamy
et al.
Carabin et

Cornelis et
al.

Table 3 – List of studies and summary of variables assessed.
* 54.5% of the 11 patients in the study are male, however 3 of the patients had FAVA and were excluded
from the study. Sex distribution of the remaining 8 patients is unknown.
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Table 4: Risk of Bias – Newcastle-Ottawa Quality Assessment Score
Author

Year

Design

Fujiwara et al.
Autrusseau et al.
Thompson et al.
Cornelis et al.
Ramaswamy et al.
Carabin et al.
Amin et al.
Cornelis et al.

2021
2020
2015
2013
2019
2020
2018
2017

Retrospective review
Retrospective review
Retrospective review
Retrospective review
Retrospective review
Retrospective review
Case Report
Prospective trial

Patients NOS for
NOS for
(n)
pain score lesion size
9
9
9
3
9
8d
3
7b,c
7b,d
4
9
9
8
7a,c
7a,d
12
8c
8d
1
9
8d
14
8b
8b

Table 4 - The Newcastle-Ottawa Quality Assessment Scale (NOS) (out of 9 stars); utilized to assess the risk
of bias.
a = Lost 1 star due to lack of satisfactory clinical follow-up
b = Lost 1 star due to lack of clearly reported procedural details
c = Lost 1 star due to lack of clearly reported change in pain scores
d = Lost 1 star due to lack of clearly reported change in lesion volume
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